What did Pacific Edge Limited announce?

Pacific Edge Limited (NZX: PEB) filed “Pacific Edge 2026 Annual Shareholders Meeting - Results” with NZX on 20 August 2026, as an agm announcement.

When was it filed?
20 August 2026
Where is the original?
NZX announcement
Pacific Edge Limited logo

Pacific Edge 2026 Annual Shareholders Meeting - Results

AGM20 August 2026PEBHealthcare

20 August 2026
PACIFIC EDGE 2026 ANNUAL SHAREHOLDERS MEETING RESULTS

DUNEDIN, New Zealand – At Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) Annual

Shareholders’ Meeting, held on 20 August 2025, shareholders were asked to vote on six

resolutions, which were supported by the Board.

As required by NZX Listing Rule 6.1, all voting was conducted by a poll. The resolutions passed by

shareholders were:

• Resolution 1: To authorise the Directors to fix the auditor’s remuneration for the ensuing

year

• Resolution 2: That Bryan Williams, who retires in accordance with NZX Listing Rule 2.7.1

and is eligible for re-election, be re-elected as a Director of the Company

• Resolution 3: That Simon Flood, who retires in accordance with NZX Listing Rule 2.7.1 and

is eligible for election, be elected as a Director of the Company

• Resolution 4: That the payment in cash of $12,699 to Simon Flood, being unpaid Director

remuneration that has accrued to him in respect of the period from 19 December 2025 to 31

March 2026 be approved for all purposes, including NZX Listing Rule 2.11.1

• Resolution 5: That the issue of 152,561,001 Shares under NZX Listing Rule 4.5.1, being

Shares issued under the Placement, Shares issued to certain participants in the Retail Offer,

and Shares issued in consideration for professional services provided in connection with the

Placement and Retail Offer, be approved and ratified for all purposes, including NZX Listing

Rule 4.5.1(c)

• Resolution 6: That the issue of 59,998,716 Shares under NZX Listing Rule 4.3.1(c), being

Shares issued to certain participants in the Retail Offer, be approved and ratified for all

purposes, including paragraph (a) of the definition of “share purchase plan” in the NZX

Listing Rules

RESOLUTION: FOR AGAINST ABSTAIN

1. Auditor’s remuneration

660,399,757

(99.94%)

407,795

(0.06%)

854,630

2. Bryan Williams re-

election


659,295,612

(99.69%)


2,075,767

(0.31%)


290,803

3. Simon Flood election


656,064,772

(99.90%)


665,264

(0.10%)


4,932,146

4. Payment to Simon

Flood


655,195,114

(99.84%)


1,080,582

(0.16%)


803,275

5. Approval of share issue

401,524,695

(99.89%)


458,733

0.11%


48,919,882

6. Issue of shares to

certain participants


610,586,164

(99.84%)


955,326

0.16%


50,120,692

2

As at the commencement of the meeting, Pacific Edge Limited had 1,241,852,687 total number of

voting shares on issue.

Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.

Investors: Media:

Dr Peter Meintjes Richard Inder

Chief Executive The Project

Pacific Edge P: +64 21 645 643

P: +64 22 032 1263

OVERVIEW

Pacific Edge: www.pacificedgedx.com

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in

the development and commercialization of bladder cancer diagnostic and prognostic tests for

patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin,

New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned,

and CLIA certified, laboratories in New Zealand and the USA.

Cxbladder: www.cxbladder.com

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of

urothelial cancer in patients presenting with hematuria and those being monitored for recurrent

disease. The tests help improve the overall patient experience, while prioritizing time and clinical

resources to optimize practice workflow and improve efficiency.

Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than

twenty-five peer reviewed publications, and Cxbladder Triage is now included in the American

Urological Association’s Microhematuria Guideline. To drive increased adoption and improved

patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies

designed to generate further clinical utility evidence.

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South

America. In the US, the test has been used by over 5,000 urologists who have ordered more than

130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public

healthcare and all residents have the option of buying the test online.

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.